Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Gastroenterology. 2022 Feb 24;162(7):2032–2046.e12. doi: 10.1053/j.gastro.2022.02.032

Figure 2. Secreted Muc5ac enriches in AT and modulates AD-MSCs of tumor-bearing mice.

Figure 2.

(A) ELISA analysis of the tissue homogenates from KC mice (n=4) demonstrates the abundant expression of Muc5ac in the pancreatic tumor and adipose tissue. The stomach serves as a positive control. (B) Immunoblot from WT (n=2) and KC mice (n=4) serum and tissue homogenates. Muc5ac was absent in WT mouse adipose and pancreas; Liver and stomach homogenates served as negative and positive controls, respectively. Arrows indicate MUC5AC protein bands. (C) Representative images of IHC for Muc5ac demonstrating its spatial localization proximal to the AD-MSCs in the KC AT, with no trace of Muc5ac in KCM and WT adipose. (D) Representative histograms and quantitative analyses from flow cytometry demonstrate significant reductions in the expression of CD44 and CD29 on the AD-MSCs isolated from KCM adipose, as compared to KC. (I) Representative histograms and (F) Quantitative analyses from flow cytometry demonstrate a significant increase in the expression of CD44 and CD29 on the AD-MSCs after treatment with KC serum with significant reductions in the Muc5ac-depleted KC serum-treated AD-MSCs. t-test *p<0.05